

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000099

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☒ Claim Nos. :

because they relate to subject matter not required to be searched by this Authority, namely :

Although claims 32-38, 41-42, and 45-46 encompass methods of treatment of a human or animal which this Authority is not obliged to search under Rule 39.1(iv) of the PCT, the search has been carried out based on the alleged effects of the compounds referred to therein.

2. ☐ Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. ☐ Claim Nos. :

because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

see extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. : 1-39, 41-42 and 45-52

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000099

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C07K 19/00, A61K 38/26, A61K 38/22, A61P 3/10, C07K 14/605, C07K 14/595

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C07K 19/00, A61K 38/26, A61K 38/22, A61P 3/10, C07K 14/605, C07K 14/595

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Delphion, Canadian Patent Database, CAPIus, Pubmed; Keywords, glucagon-like peptide agonist, GLP agonist, exendin, gastrin, CCK, cholecystokinin, blood glucose, diabetes, insulin

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US5545618 B1 (BUCKLEY DL et al. ) 13 August 1996	29, 32-37, 39, 41-42, 45-52
A	US6506724 B1 (AMYLIN PHARMACEUTICALS, INC., HILES RA.et al.) 14 January 2003	29, 32-37, 39, 41-42, 45-52
P, X	WO2004037195 A2 (WARATAH PHARMACEUTICALS, INC., BRAND SJ. et al.) 6 May 2004 whole document	1-19, 32-39, 41-42 and 47-48

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 June 2005 (20-06-2005)

Date of mailing of the international search report

20 July 2005 (20-07-2005)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001(819)953-2476

Authorized officer

Nicole Harris (819) 997-4541

10/587529

IAP11 Rec'd PCT/PTO 26 JUL 2006

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000099

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO2004045640 A1 (WARATAH PHARMACEUTICALS, INC., CRUZ A) 3 June 2004	1-20, 25, 29, 32-39, 41-42, 47-48 and 51
P, Y	whole document	21-24, 26-28, 45-46, 49-50 and 52
P, A	WO2004096853 A1 (WARATAH PHARMACEUTICALS, INC., BRAND SJ. et al.) 11 November 2004	
P, A	WO2004105780 A2 (WARATAH PHARMACEUTICALS, INC., CRUZ A) 9 December 2004	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.  
PCT/CA2005/000099

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US5545618	13-08-1996	WO9111457 A1	08-08-1991
		CA2073856 A1	25-07-1991
		DE69129226D D1	14-05-1998
		DE69129226T T2	30-07-1998
		EP0512042 A1	11-11-1992
		ES2113879T T3	16-05-1998
		JP3262329B2 B2	04-03-2002
		JP2001151798 A	05-06-2001
		JP2003192698 A	09-07-2003
		JP2004196825 A	15-07-2004
		JP 2005132848A	26-05-2005
US6506724	14-01-2003	AU778002 B2	11-11-2004
		AU5284600 A	18-12-2000
		AU2005200608 A1	10-03-2005
		CA2373266 A1	07-12-2000
		EP1181043 A2	27-02-2002
		JP2003501361T T	14-01-2003
		US2004023871 A1	05-02-2004
		WO0073331 A2	07-12-2000
WO2004037195	06-05-2004	AU2003243501 A1	22-12-2003
		AU2003283004 A1	13-05-2004
		AU2003285229 A1	15-06-2004
		CA2486584 A1	18-12-2003
		EP1511509 A1	09-03-2005
		US2004023885 A1	05-02-2004
		US2004209801 A1	21-10-2004
		US2004229810 A1	18-11-2004
		US2004266682 A1	30-12-2004
		WO03103701 A1	18-12-2003
		WO2004045640 A1	03-06-2004
WO2004045640	03-06-2004	AU2003243501 A1	22-12-2003
		AU2003283004 A1	13-05-2004
		AU2003285229 A1	15-06-2004
		CA2486584 A1	18-12-2003
		EP1511509 A1	09-03-2005
		US2004023885 A1	05-02-2004
		US2004209801 A1	21-10-2004
		US2004229810 A1	18-11-2004
		US2004266682 A1	30-12-2004
		WO03103701 A1	18-12-2003
		WO2004037195 A2	06-05-2004
WO2004096853	11-11-2004	None	
WO2004105780	09-12-2004	AU722004 B2	20-07-2000
		AU774746 B2	08-07-2004
		AU1331900 A	18-08-2000
		AU2003231864 A1	12-12-2003
		AU2004218687 A1	04-11-2004
		CA2326741 A1	03-08-2000
		CA2494134 A1	04-12-2003
		EP1071447 A1	31-01-2001
		EP1509087 A2	02-03-2005
		IL138784D D0	31-10-2001
		JP2004506591T T	04-03-2004
		SE0003508 A	21-11-2000
		US5885956 A	23-03-1999
		US6288301 B1	11-09-2001
		US6558952 B1	06-05-2003
		US2002081285 A1	27-06-2002
		US2004037818 A1	26-02-2004
		US2004209816 A1	21-10-2004
		WO0044400 A1	03-08-2000
		WO03100024 A2	04-12-2003

BEST AVAILABLE COPY

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000099

continuation of Box III

Group 1: Claims 1-31, 32(partially), 33-37, 38(partially), 39, 41-42(partially), 45-52(partially) are directed towards GLP-1 agonist and gastrin compositions and their use in regulating blood glucose levels.

Group 2: Claims 32 (partially), 38 (partially), 41(partially), and 45-52 (partially) are directed towards methods of treating or preventing disease using GLP-1 agonist and gastrin compositions.

Group 3: Claims 40, 41-42 (partially), 43-44 and 45-46(partially) and 49-52(partially) are directed towards contacting islet precursor cells with GLP-1 agonist and gastrin to induce islet neogenesis.

BEST AVAILABLE COPY